Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology – the first of which is now commercially available
Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, announced it has received the 2024 MedTech Breakthrough Award for Best New Technology Solution in the Cardiology category. The recognition is for Anumana’s suite of artificial intelligence (AI)-based electrocardiogram (ECG) interpretation algorithms, with a spotlight on ECG-AI™ LEF, the company’s FDA cleared, breakthrough AI algorithm using routine 12-lead ECG data to detect Low Ejection Fraction (LEF).
Developed in collaboration with Mayo Clinic, Anumana’s ECG-AI LEF represents a paradigm shift in ECG interpretation. LEF, or a weak heart pump, is a significant, at times asymptomatic, and commonly undiagnosed indicator of heart failure.1 The increasing prevalence of heart failure and its associated morbidity, mortality, rehospitalizations, and societal costs underscore the need to identify and manage patients with LEF. ECG-AI LEF is an innovative software-as-a-medical device (SaMD) designed to help clinicians identify LEF in adults earlier by using data from a routine 12-lead ECG, a rapid standard of care test used across primary and specialty care settings. The AI algorithm was clinically validated in a multi-site, retrospective study of 16,000 patients, demonstrating an 84.5% sensitivity and 83.6% specificity.4 Additionally, in a randomized controlled prospective study with 22,641 adults, an investigational version of the algorithm demonstrated the ability to improve primary care clinicians’ diagnoses of LEF by +31% versus standard of care without increasing the overall rate of echocardiogram usage.5 ECG-AI LEF received U.S. FDA clearance in September 2023 and is currently under review in Europe.
Also Read: Sorcero Generative AI Platform Achieves Breakthrough in Patient Accessibility
Beyond ECG-AI LEF, Anumana has the largest and most robust pipeline of ECG-AI algorithms in development, including three additional FDA Breakthrough Device-designated algorithms (pulmonary hypertension, cardiac amyloidosis, and hyperkalemia), founded on more than six years of pioneering ECG-AI research and development at Mayo Clinic, including nearly 100 studies to date.
“At Anumana, we are committed to developing evidence-based AI algorithms that empower clinicians to uncover diseases earlier and improve patient outcomes,” said Maulik Nanavaty, CEO of Anumana. “We are honored to be recognized by MedTech Breakthrough for our efforts in developing and implementing our cutting edge clinically validated AI algorithms that enhance ECG interpretation. Our ECG-AI algorithm technology represents a groundbreaking shift in the utility of ECG, and we are excited to be at the forefront of improving cardiovascular care with AI technology.”
The MedTech Breakthrough Awards, organized by Tech Breakthrough, an independent, leading market intelligence organization, honors excellence in medical and health related technology, products, services, and people.
Source: BusinessWire
